Amgen's shares rise on CEO's optimism about early MariTide obesity drug trial results, targeting $80bn anti-obesity market.

Amgen's shares surged after CEO, Robert Bradway, expressed optimism about early results from a trial of the company's experimental obesity drug, MariTide. This comes as the demand for anti-obesity drugs is expected to reach $80bn, making Amgen a potential competitor to Eli Lilly & Co. and Novo Nordisk A/S. The Thousand Oaks, California-based company is developing an alternative approach to obesity treatment.

Articles

Yahoo Finance

Livemint

Biztoc

BNN Bloomberg

Investor's Business Daily

NBC New York

NBC Philadelphia

Bloomberg

-- show less --

Further Reading

Related Stories